Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US7170811035
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BR2B91
PFE
Pfizer Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Drug Manufacturers - General · THEMEFOLIO: $TF-77
NAME
Pfizer Inc
ISIN
US7170811035
TICKER
PFE
MIC
XNYS
REUTERS
PFE.N
BLOOMBERG
PFE US
Tue, 23.09.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 4, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2025 Performance Report, to be issued that mo...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) and Metsera, Inc. (NASDAQ: MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portf...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.09.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY® (COVID-19 Vaccine, mRNA) 2025-2026 Formula in adults aged 65 and olde...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.08.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and old...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Fri, 25.07.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1) for active immunization to prevent CO...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.07.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio’s proprietary CLF2 platform. This agreement...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.07.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitiv...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.06.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-weekly subcutaneous HY...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.06.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The third-quarter 2025 cash dividend will be the 347th consecutive quarterly dividend paid by...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.06.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2025 Performance Report, to be issued that mor...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 03.06.2025       Pfizer
US7170811035

PHILADELPHIA, June 3, 2025 /PRNewswire/ -- Berger Montague advises shareholders of Pfizer Inc. ("Pfizer" or the "Company") (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera. ...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.06.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Fri, 30.05.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a B...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.05.2025       Pfizer
US7170811035

A Case Management Conference (CMC) in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Friday, 30 May at 9:00am CT in the United States Courthouse is Pensacola, Florida. The litigation is being brought on behalf of women in the USA who developed meningiomas after receiving at least 4 consecutive injections of Pfizer’...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.05.2025       Pfizer
US7170811035

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Tue, 20.05.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Pfizer
US7170811035

Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird cum Dividende/Zinsen gehandelt am 08.05.2025 und ex Dividende/Zinsen am 09.05.2025 The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its pre-dividend/interest day on 08.05.2025 and its ex-dividend/interest day on 09.05.2025...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.04.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving impr...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Sat, 26.04.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder canc...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.04.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfiz...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 23.04.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30 to June 3 in Chicago. Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral prese...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.04.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.04.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management. Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (NCT06567327 and NCT06568731) met key pharm...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.04.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24, 2025. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who participate will be afforded comparable rights and opportunities...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Tue, 01.04.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individu...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.03.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2025 Performance Report, to be issued that morn...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.02.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 10:30 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at www.pfizer.com/investors....
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.02.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), demonstrating a statistically significant and clinically meaningful improvement in over...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.02.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), includ...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.02.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced additional follow-up results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) evaluating the efficacy and safety of PADCEV ® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus KEYTRU...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.02.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance(5) provided on December 17, 2024. The fourth-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pfiz...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.02.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) harboring a B...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.01.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February 13-15 in San Francisco, California. Data from more than 20 company-sponsored, investigator-sponsored, and collaborative research abstracts...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Sat, 25.01.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, th...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.01.2025       Pfizer
US7170811035

Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird ex Dividende/Zinsen gehandelt am 24.01.2025 The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its ex-dividend/interest day on 24.01.2025...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.01.2025       Pfizer
US7170811035

Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird cum Dividende/Zinsen gehandelt am 23.01.2025 und ex Dividende/Zinsen am 24.01.2025 The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its pre-dividend/interest day on 23.01.2025 and its ex-dividend/interest day on 24.01.2025...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.01.2025       Pfizer
US7170811035

Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird cum Dividende/Zinsen gehandelt am 23.01.2025 und ex Dividende/Zinsen am 24.01.2025 The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its pre-dividend/interest day on 23.01.2025 and its ex-dividend/interest day on 24.01.2025...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.01.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder ca...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.01.2025       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.com/inves...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.12.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.12.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2024 Performance Report, to be...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.12.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance(1) and reaffirmed its October 29, 2024 full-year 2024 guidance(1). The accompanying presentation can be found at www.pfizer.com/investors. Full-Year 2025 Revenue Guidance(1) Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes t...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.12.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will b...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.12.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) today announced results from the Phase 3 PATINA trial demonstrating that the addition of IBRANCE® (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.12.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:30 a.m. EST on Tuesday, December 17, 2024. The purpose of the call is to provide Pfizer’s full-year 2025 financial guidance. To view and listen to the webcast, visit our web site at www.pfizer.com/in...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.12.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) will highlight the latest advancements from its growing hematology and breast cancer portfolios at the American Society of Hematology (ASH) Annual Meeting & Exposition (December 7-10) and the San Antonio Breast Cancer Symposium (SABCS, December 10-13). Data from more than 100 company-sponsored, investigator-sponsored, a...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.11.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.11.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A (congenital factor VIII [FVIII] deficiency, FVIII <1%) without FVIII inh...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.11.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Andrew Baum, Chief Strategy and Innovation Officer, Executive Vice President, and Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 9:00...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.11.2024       Pfizer
US7170811035

Das Instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY wird ex Dividende/Zinsen gehandelt am 08.11.2024 The instrument PFE US7170811035 PFIZER INC. DL-,05 EQUITY has its ex-dividend/interest day on 08.11.2024...
Read more
Pfizer
Technical Analysis Termsheets Terminal
Permalink